๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma

โœ Scribed by Francisco J. Esteva-Lorenzo; John E. Janik; Robert G. Fenton; Alison Emslie-Smith; Andrew G. Engel; Dan L. Longo

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
529 KB
Volume
76
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Infusional floxuridine-based therapy for
Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma
โœ David M. Reese; Michelle Corry; Eric J. Small ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 77 KB ๐Ÿ‘ 2 views

## BACKGROUND. The treatment of patients with metastatic renal cell carcinoma (RCC) continues to pose a major clinical challenge. Previous studies have suggested that infusional floxuridine (FUDR) has antitumor efficacy and is well tolerated. To the authors knowledge the combination of infusional F

Clinical factors associated with outcome
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
โœ Toni K. Choueiri; Jorge A. Garcia; Paul Elson; Mohamad Khasawneh; Saif Usman; Al ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 124 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell carcinoma (RCC). The identification of patients who are more likely to benefit from these agents is warranted. ## METHODS. In to